BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Ion Beam Applications

Avatud

10.6 5.79

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.02

Max

10.64

Põhinäitajad

By Trading Economics

Sissetulek

-10M

Müük

206M

P/E

Sektori keskmine

36.815

57.333

Dividenditootlus

1.71

Kasumimarginaal

-4.99

Töötajad

1,943

EBITDA

-372K

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.71%

2.63%

Turustatistika

By TradingEconomics

Turukapital

295M

Eelmine avamishind

4.81

Eelmine sulgemishind

10.6

Ion Beam Applications Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. sept 2024, 06:28 UTC

Omandamised, ülevõtmised, äriostud

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Võrdlus sarnastega

Hinnamuutus

Ion Beam Applications Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.